Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

72 hr Manufacturer Dornase alfa Pulmozyme (Genentech) 24 hr Prescribing information Epoetin alfa multidose Procrit (Ortho Biotech) 7 days Manufacturer Epoetin alfa single dose Procrit (Ortho ...

Reblozyl was found to be superior to standard ESA therapy with Amgen and Johnson & Johnson's Epogen/Procrit (epoetin alfa) at achieving those objectives, with almost 59% of patients on BMS' drug ...

HIF-PHI drugs activate a red blood cell-generating response that occurs naturally when reduced oxygen levels are detected in the blood, and work in a different way to ESAs like epoetin alfa and ...

Thomas W. LeBlanc, MD, MA, discusses how the COMMANDS study, which compared luspatercept to epoetin alfa in erythropoiesis-stimulating agent (ESA)–naive, transfusion-dependent patients with low-risk ...

Immunology, filgrastim, epoetin alfa, and insulin glargine were named the slowest growing biosimilar markets, averaging only 26% market share after 5 years. For oncology biosimilars, WAC prices offer ...

DelveInsight’s ‘Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an ...

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...